HOME
Lang:
Anemia · Kidney DiseaseAnemia · Sakit sa BatoAnemia · Sakit sa KidneyAnemia · Sakit king Batu
Nephrology · Internal Medicine · Clinical Reference

When EPO Stops Working: Understanding "EPO-Resistant" Anemia of Kidney DiseaseKapag Hindi Na Tumatalab ang EPO: Pag-unawa sa "EPO-Resistant" Anemia sa Sakit sa BatoKung Dili Na Motrabaho ang EPO: Pagsabot sa "EPO-Resistant" Anemia sa Sakit sa KidneyNung Ali Na Tumatalab ing EPO: Pamag-intindi king "EPO-Resistant" Anemia king Sakit king Batu

ESA Hyporesponsiveness in CKD: A Mechanism-First Clinical Guide

Why hemoglobin can stall even on growing doses of erythropoietin — and the causes worth fixing before the dose climbs into the harm zone.Bakit maaaring hindi tumaas ang hemoglobin kahit lumalaki na ang dose ng erythropoietin — at ang mga sanhi na dapat ayusin bago umakyat pa ang dose papunta sa mapanganib na antas.Nganong dili motaas ang hemoglobin bisan padaghan ang dose sa erythropoietin — ug ang mga hinungdan nga angay ayohon sa dili pa mosaka ang dose ngadto sa makadaot nga lebel.Bakit ali pamungat ing hemoglobin kahit lumalaki na ing dose ning erythropoietin — at ing deng sanhi a dapat ayusin bayu umakyat ing dose papunta king mapanganib a lebel.

KDIGO 2026-aligned: the hepcidin–iron axis, a cause-directed workup, and the integrative therapeutic ladder — iron, HIF-PHIs, vitamin D, L-carnitine — when ESA escalation fails.

PublishedNailathalaGipatikPepalwal: ReferencesMga SanggunianMga TinubdanReng Reperensya: 39 Read timeOras ng pagbasaOras sa pagbasaOras ning pamamasa:
Circular vignette hero illustration for the EPO-resistant renal anemia guide.
01 · The basics01 · Mga pangunahin01 · Mga sukaranan01 · Deng pangunahin

Understanding "EPO-Resistant" anemia of kidney diseasePag-unawa sa "EPO-Resistant" anemia sa sakit sa batoPagsabot sa "EPO-Resistant" anemia sa sakit sa kidneyPamag-intindi king "EPO-Resistant" anemia king sakit king batu

Editorial illustration: a Filipino dialysis patient receiving an erythropoietin injection — the central image of EPO-resistant renal anemia care.
EPO is the "go" signal for red blood cells. When the marrow stops responding, the cause is almost always something blocking the signal — not the signal itself.Ang EPO ang "go" signal para sa pulang selula ng dugo. Kapag hindi na tumutugon ang utak ng buto, ang sanhi ay halos palaging may humaharang sa signal — hindi ang signal mismo.Ang EPO mao ang "go" signal alang sa pulang selula sa dugo. Kung dili na motubag ang utok sa bukog, ang hinungdan halos kanunay adunay nagpugong sa signal — dili ang signal mismo.Ing EPO ya ing "go" signal para king pulang selula ning daya. Nung ali na tumutugon ing utak ning butu, ing sanhi halos palaging atin humaharang king signal — ali ing signal mismo.

Healthy kidneys make a hormone called erythropoietin (EPO) that tells your bone marrow to build red blood cells. When kidneys are damaged, they make less EPO — so you can become anemic and feel tired, short of breath, cold, or weak. To help, your kidney doctor may prescribe an EPO-like injection (an ESA, or "erythropoiesis-stimulating agent"). For most patients, this works well.Ang malulusog na bato ay gumagawa ng hormon na tinatawag na erythropoietin (EPO) na nag-uutos sa utak ng buto na gumawa ng mga pulang selula ng dugo. Kapag may pinsala ang bato, mas kaunting EPO ang nagagawa — kaya maaari kang magka-anemia at maramdamang pagod, hingal, lamig, o manghina. Para tumulong, maaaring magreseta ang iyong doktor ng EPO-like na iniksyon (isang ESA, o "erythropoiesis-stimulating agent"). Sa karamihan, mahusay itong gumagana.Ang himsog nga kidney naghimo og hormon nga gitawag og erythropoietin (EPO) nga nagsugo sa utok sa bukog nga maghimo og mga pulang selula sa dugo. Kung adunay danyos ang kidney, gamay ra ang EPO nga mahimo — busa mahimo ka magka-anemia ug mobati og kapoy, kapulgi, katugnaw, o kaluya. Aron makatabang, mahimong magreseta ang imong doktor og EPO-like nga iniksyon (usa ka ESA, o "erythropoiesis-stimulating agent"). Sa kadaghanan, maayo kining molihok.Ing malulusog a batu ya gumagawa ning hormon a tinatawag a erythropoietin (EPO) a nag-uutos king utak ning butu a gumawa ning deng pulang selula ning daya. Nung atin pinsala ing batu, mas kaunting EPO ing nagagawa — kaya pwedeng magka-anemia ka at maramdamang pagod, hingal, lamig, o manghina. Para tumulong, pwedeng magreseta ing kekang doktor ning EPO-like a iniksyon (metung a ESA, o "erythropoiesis-stimulating agent"). King karamihan, mahusay itong gumagana.

But sometimes the marrow does not respond — even at higher doses. We call this "EPO resistance" or hyporesponsiveness. The important truth is this: it almost always means something else is getting in the way of making red cells — not that your body has stopped listening to EPO. Finding and fixing that "something else" is far safer and more effective than just pushing the dose higher.Pero minsan, hindi tumutugon ang utak ng buto — kahit tumaas na ang dose. Tinatawag itong "EPO resistance" o hyporesponsiveness. Ang mahalagang katotohanan: halos palaging may ibang bagay na humaharang sa paggawa ng mga pulang selula — hindi na hindi nakikinig ang katawan sa EPO. Mas ligtas at mas epektibong hanapin at ayusin ang "ibang bagay" na iyon kaysa basta itaas ang dose.Apan usahay, dili motubag ang utok sa bukog — bisan misaka na ang dose. Gitawag namo kining "EPO resistance" o hyporesponsiveness. Ang importanting kamatuoran: halos kanunay adunay laing butang nga nagpugong sa paghimo og pulang selula — dili nga wala na maminaw ang lawas sa EPO. Mas luwas ug mas epektibo ang pagpangita ug pag-ayo sa "laing butang" nga kana kaysa basta-basta nga pagsaka sa dose.Pero misan, ali tumutugon ing utak ning butu — kahit tumaas na ing dose. Tinatawag mi ining "EPO resistance" o hyporesponsiveness. Ing mahalagang katotohanan: halos palaging atin aliwa a bagay a humaharang king paggawa ning deng pulang selula — ali a ali na makikinig ing bangkî king EPO. Mas ligtas at mas epektibong hanapin at ayusin ing "aliwa a bagay" a yan kesa basta itaas ing dose.

💡

The key ideaAng susing ideyaAng sentro nga ideyaIng susing ideya

EPO resistance is rarely a failure of the marrow to "hear" the signal. It is almost always a failure of substrate (iron the marrow can actually use) and a hostile inflammatory environment. Fix those, and the marrow usually starts working again — at a much safer EPO dose.Bihirang totoong tumigil sa pakikinig ang utak ng buto. Halos palaging kulang sa materyales (iron na talagang magagamit ng utak ng buto) at may matinding pamamaga sa katawan. Kapag inayos ang mga ito, kadalasang magsisimulang gumana ulit ang utak ng buto — sa mas ligtas na dose ng EPO.Panagsa ra nga tinuod nga mihunong sa pagpaminaw ang utok sa bukog. Halos kanunay kulang sa materyales (iron nga magamit gayud sa utok sa bukog) ug adunay grabe nga pamamaga sa lawas. Kung ayohon kini, kasagaran mosugod og molihok pag-usab ang utok sa bukog — sa mas luwas nga dose sa EPO.Bihirang totoong tumigil king pakikinig ing utak ning butu. Halos palaging kulang king materyales (iron a talagang magagamit ning utak ning butu) at atin matinding pamamaga king bangkî. Nung inayos ing deng ini, kadalasan magsisimulang gumana pasibayu ing utak ning butu — king mas ligtas a dose ning EPO.

02 · Why it happens02 · Bakit ito nangyayari02 · Nganong nahitabo kini02 · Bakit ini nangyayari

The most common reasons EPO stops workingMga karaniwang dahilan kung bakit hindi na umuubra ang EPOMga kasagarang hinungdan nganong dili na molihok ang EPODeng karaniwang dahilan kung bakit ali na umuubra ing EPO

🩸 Low iron — or iron that is "locked away"Mababang iron — o iron na "nakakulong"Ubos nga iron — o iron nga "nakulong"Mababang iron — o iron a "makulong"

The number-one cause. Even when iron stores look normal on a blood test, inflammation can trap iron inside cells so the marrow cannot reach it. This is why IV iron — not just iron pills — is usually needed in dialysis.Pinakanumero unong sanhi. Kahit normal ang itsura ng iron sa blood test, ang pamamaga ay maaaring magkulong sa iron sa loob ng mga selula kaya hindi ito maabot ng utak ng buto. Kaya kailangan ng IV iron sa dialysis — hindi lang iron pills.Numero uno nga hinungdan. Bisan normal ang iron sa blood test, ang pamamaga makapatipig sa iron sulod sa mga selula busa dili kini maabot sa utok sa bukog. Mao nga IV iron ang gikinahanglan sa dialysis — dili lang iron pills.Pinakanumero unong sanhi. Kahit normal ing itsura ning iron king blood test, ing pamamaga ya pwedeng magkulong king iron king lub ning deng selula kaya ali ini maabot ning utak ning butu. Kaya kailangan ning IV iron king dialysis — ali la iron pills.

🔥 Inflammation or hidden infectionPamamaga o nakatagong impeksyonPamamaga o tinago nga impeksyonPamamaga o makatagong impeksyon

Infections you may not feel — a quiet dental abscess, a dialysis catheter, a foot ulcer, a failed graft — release proteins that trap iron and tell the marrow to slow down. Cleaning these up often restores EPO response.Mga impeksyong maaaring hindi mo maramdaman — tahimik na ngipin na abscess, dialysis catheter, sugat sa paa, palpak na graft — ay naglalabas ng mga protina na nagkukulong sa iron at nagpapabagal sa utak ng buto. Kapag nalinis ang mga ito, madalas na nakakabalik ang tugon sa EPO.Mga impeksyon nga mahimo dili nimo bation — hilom nga abscess sa ngipon, dialysis catheter, samad sa tiil, napakyas nga graft — nagpagawas og mga protina nga nagkulong sa iron ug nagsugo sa utok sa bukog nga maghinay. Kung mahinloan kini, kasagaran mobalik ang tubag sa EPO.Deng impeksyong pwedeng ali mu maramdaman — tahimik a ngipin a abscess, dialysis catheter, sugat king bitis, palpak a graft — ya naglalabas ning deng protina a nagkukulong king iron at nagpapabagal king utak ning butu. Nung nalinis ing deng ini, madalas a nakakabalik ing tugon king EPO.

🦴 Overactive parathyroid glandsSobrang aktibong parathyroid glandsSobrang aktibong parathyroid glandsSobrang aktibong parathyroid glands

In advanced kidney disease, the parathyroid glands can become overactive (high PTH on labs). Very high PTH replaces healthy marrow with scar tissue and blunts EPO response. Vitamin D, phosphate binders, calcimimetics, or surgery can help.Sa advanced na sakit sa bato, maaaring maging sobrang aktibo ang parathyroid glands (mataas ang PTH sa labs). Ang napakataas na PTH ay pumapalit sa malusog na utak ng buto ng peklat at nagpapabagal sa tugon sa EPO. Makakatulong ang vitamin D, phosphate binders, calcimimetics, o operasyon.Sa advanced nga sakit sa kidney, mahimong sobrang aktibo ang parathyroid glands (taas ang PTH sa labs). Ang taas kaayong PTH nagpuli sa himsog nga utok sa bukog og scar tissue ug nagpahinay sa tubag sa EPO. Makatabang ang vitamin D, phosphate binders, calcimimetics, o operasyon.King advanced a sakit king batu, pwedeng maging sobrang aktibo ing parathyroid glands (mataas ing PTH king labs). Ing napakataas a PTH ya pumapalit king malusog a utak ning butu ning peklat at nagpapabagal king tugon king EPO. Makakatulong ing vitamin D, phosphate binders, calcimimetics, o operasyon.

🍚 Poor nutrition or weight lossMahinang nutrisyon o pagbaba ng timbangMahinang nutrisyon o paghulog sa timbangMahinang nutrisyon o pagbaba ning timbang

Protein-energy wasting — losing muscle and protein — strongly predicts a poor EPO response. Adequate protein at meals (especially around dialysis), enough calories, and treating the appetite-killing parts of CKD are foundational.Ang protein-energy wasting — pagkawala ng muscle at protina — ay malakas na nag-aabiso ng mahinang tugon sa EPO. Mahalaga ang sapat na protina sa bawat kain (lalo na sa paligid ng dialysis), sapat na calories, at paggamot sa mga sanhi ng pagkawala ng gana.Ang protein-energy wasting — pagkawala sa kaunuran ug protina — kusgan nga nagpamatuod sa mahinang tubag sa EPO. Importante ang sapat nga protina matag pagkaon (labi na sa palibot sa dialysis), sapat nga calories, ug pagtambal sa mga hinungdan sa pagkawala sa gana.Ing protein-energy wasting — pagkawala ning muscle at protina — ya makapangang nag-aabiso ning mahinang tugon king EPO. Mahalaga ing sapat a protina king bawat kain (lalo na king paligid ning dialysis), sapat a calories, at paggamut king deng sanhi ning pagkawala ning gana.

💧 Not enough dialysisHindi sapat na dialysisDili sapat nga dialysisAli sapat a dialysis

If dialysis is under-prescribed or sessions get cut short, uremic toxins build up. Some of these toxins (like indoxyl sulfate) directly suppress red-cell production and shorten the lifespan of the cells that do get made.Kung kulang ang reseta ng dialysis o pinaiikli ang mga session, naipon ang mga uremic toxin. Ang ilan sa mga ito (tulad ng indoxyl sulfate) ay direktang pumipigil sa paggawa ng pulang selula at pinaikli ang buhay ng mga selulang nagagawa.Kung kulang ang reseta sa dialysis o gipamubo ang mga session, magpundok ang mga uremic toxin. Ang uban niini (sama sa indoxyl sulfate) direkta nga nagpugong sa paghimo og pulang selula ug nagpamubo sa kinabuhi sa mga selula nga nahimo.Nung kulang ing reseta ning dialysis o pinaiikli ing deng session, naipon ing deng uremic toxin. Ing aliwa king deng ini (kapariho ning indoxyl sulfate) ya direktang pumipigil king paggawa ning pulang selula at pinaikli ing biye ning deng selulang nagagawa.

🌿 Low vitamin D, B12, or folateMababang vitamin D, B12, o folateUbos nga vitamin D, B12, o folateMababang vitamin D, B12, o folate

These vitamins are quiet partners for the marrow. Vitamin D also dampens inflammation. Replacing them is cheap, safe, and can meaningfully improve the response to EPO when levels are low.Ang mga bitaminang ito ay tahimik na katuwang ng utak ng buto. Ang vitamin D ay nakakapagpababa rin ng pamamaga. Ang pagpapalit sa mga ito ay mura, ligtas, at maaaring makatulong nang malaki sa tugon sa EPO kapag mababa ang antas.Kining mga bitamina hilom nga kauban sa utok sa bukog. Ang vitamin D nagpaubos usab sa pamamaga. Ang pag-puli niini barato, luwas, ug mahimong makatabang og dako sa tubag sa EPO kung ubos ang lebel.Ing deng bitaminang ini ya tahimik a katuwang ning utak ning butu. Ing vitamin D ya nakakapagpababa mu ning pamamaga. Ing pagpapalit king deng ini ya mura, ligtas, at pwedeng makatulong nang malaki king tugon king EPO nung mababa ing antas.

🩸 Hidden blood lossNakatagong pagkawala ng dugoTinago nga pagkawala sa dugoMakatagong pagkawala ning daya

Slow bleeding from the gut, frequent blood draws, blood left in the dialysis circuit, or heavy periods all drain iron. Stool tests, upper-GI evaluation, or gynecologic review may be needed.Mabagal na pagdurugo sa bituka, madalas na blood draws, dugo na naiwan sa dialysis circuit, o malakas na regla ay nag-aalis ng iron. Maaaring kailanganin ang stool tests, upper-GI evaluation, o gynecologic review.Hinay nga pagdugo sa tinai, kanunay nga blood draws, dugo nga nahabilin sa dialysis circuit, o kusog nga regla nagpaubos sa iron. Mahimong gikinahanglan ang stool tests, upper-GI evaluation, o gynecologic review.Mabagal a pagdurugo king bituka, madalas a blood draws, daya a naiwan king dialysis circuit, o makalat a regla ya nag-aalis ning iron. Pwedeng kailanganin ing stool tests, upper-GI evaluation, o gynecologic review.

⛔ A rare reaction to the EPO itselfMga bihirang reaksyon sa EPO mismoTalagsa nga reaksyon sa EPO mismoBihirang reaksyon king EPO mismo

Very rarely, the body makes antibodies that block EPO completely. This shows up as a sudden fall in hemoglobin with no new red cells being made — and is a medical urgency. Your doctor screens for this when hemoglobin crashes on therapy.Napakabihira, gumagawa ng antibodies ang katawan na ganap na humaharang sa EPO. Ipinapakita ito ng biglaang pagbaba ng hemoglobin na walang bagong pulang selula — isang medikal na agarang sitwasyon. Sinusuri ng doktor mo ito kapag biglaang bumagsak ang hemoglobin sa therapy.Talagsa kaayo, naghimo og antibodies ang lawas nga hingpit nga nagpugong sa EPO. Magpakita kini sa kalit nga paghulog sa hemoglobin nga walay bag-ong pulang selula — usa ka medikal nga emergency. Susihon kini sa imong doktor kung kalit nga mihulog ang hemoglobin sa therapy.Napakabihira, gumagawa ning antibodies ing bangkî a ganap a humaharang king EPO. Ipinapakita ini ning biglaang pagbaba ning hemoglobin a alang bagong pulang selula — metung a medikal a agarang sitwasyon. Sinusuri ning doktor mu ini nung biglaang bumagsak ing hemoglobin king therapy.

03 · The plan03 · Ang plano03 · Ang plano03 · Ing plano

What we do — fix the cause, don't just push the doseAng ginagawa namin — ayusin ang sanhi, hindi basta itaas ang doseAng among ginabuhat — ayohon ang hinungdan, dili basta isaka ang doseIng gagawan mi — ayusin ing sanhi, ali basta itaas ing dose

Six-step ladder figure showing the safer plan for EPO-resistant anemia — find & fix the cause, replace iron, hunt hidden infection, balance PTH & minerals, optimize dialysis & nutrition, add HIF-PHI & adjuncts — beside a 'DON'T just push the EPO dose' red caution panel.

A six-step ladder shows what your kidney team does — in order — when EPO is not working: find the cause, replace iron (often IV), hunt hidden infection, balance PTH and minerals, optimize dialysis and nutrition, and consider a HIF-PHI medicine. Beside it sits a red "DON'T just push the EPO dose" panel — pushing higher doses raises the risk of stroke and heart problems without making you feel better.

Two decades of large trials have taught us one critical lesson: forcing the hemoglobin all the way up to normal with very high EPO doses causes more strokes, more heart problems, and more deaths — without making people feel better. That is why your kidney doctor aims for a steady, safer hemoglobin of about 10–11.5 g/dL and looks for the real cause when the medicine stops working — instead of stacking the dose higher.Dalawang dekada ng malalaking pag-aaral ang nagturo ng isang mahalagang aral: ang pilitin ang hemoglobin pataas sa normal gamit ang napakataas na dose ng EPO ay nagdudulot ng mas maraming stroke, problema sa puso, at kamatayan — nang hindi gumagaling ang pakiramdam. Kaya nilalayon ng iyong doktor ang matatag, mas ligtas na hemoglobin na mga 10–11.5 g/dL at hinahanap ang totoong sanhi kapag tumitigil ang gamot — sa halip na itaas pa ang dose.Duha ka dekada sa dagkong pagtuon nagtudlo og usa ka importante nga leksyon: ang pagpugos sa hemoglobin paingon sa normal gamit ang taas kaayo nga dose sa EPO nagdala og mas daghang stroke, problema sa kasingkasing, ug kamatayon — nga walay paggawas sa pamati. Mao nga gipangita sa imong doktor ang malig-on, mas luwas nga hemoglobin nga mga 10–11.5 g/dL ug gipangita ang tinuod nga hinungdan kung mihunong ang tambal — kaysa pagsaka pa sa dose.Adwang dekada ning malalaking pag-aaral ing nagturo ning metung a mahalagang aral: ing pilitin ing hemoglobin pataas king normal gamit ing napakataas a dose ning EPO ya nagdudulot ning mas dacal a stroke, problema king pusu, at kamatayan — nang ali gumagaling ing pakiramdam. Kaya nilalayon ning kekang doktor ing matatag, mas ligtas a hemoglobin a mga 10–11.5 g/dL at hinahanap ing totoong sanhi nung tumitigil ing gamut — king halip na itaas pa ing dose.

In practice, the plan looks like this:Sa praktika, ganito ang plano:Sa praktika, mao kini ang plano:King praktika, ganini ing plano:

04 · What you can do04 · Ang iyong magagawa04 · Ang imong mahimo04 · Ing kekang magagawa

What you can do to help your treatment workPaano mo matutulungan ang iyong gamutan na umubraUnsaon nimo pagtabang sa imong pagtambal nga molihokPaano mu matutulungan ing kekang gamutan na umubra

✅

Five practical thingsLimang praktikal na bagayLima ka praktikal nga butangLimang praktikal a bagay

1. Take iron and other supplements exactly as prescribed, and keep your lab appointments — your iron and inflammation are tracked by blood tests.
2. Tell us about any signs of infection (fever, redness or pus at your access site, dental pain, foot wounds), bleeding (black or red stools, heavy periods, nosebleeds), or new fatigue.
3. Complete your full dialysis sessions — even when you feel tired or have somewhere to be — and follow your nutrition plan with enough protein.
4. Ask before starting any new supplement, herbal product, or "energy" drink — many of them quietly interfere with iron, EPO, or your kidneys.
5. Bring this guide and your questions to your next visit. Our goal is a steady, safe hemoglobin — not a "perfect" lab number. Feeling better and staying safe matter more than the value alone.1. Inumin ang iron at iba pang supplements ayon sa reseta, at huwag laktawan ang mga lab appointments — sinusubaybayan ang iyong iron at pamamaga sa pamamagitan ng blood tests.
2. Sabihin sa amin ang anumang tanda ng impeksyon (lagnat, pamumula o nana sa access site, sakit ng ngipin, sugat sa paa), pagdurugo (itim o pulang dumi, malakas na regla, balinguyngoy), o bagong pagod.
3. Tapusin ang buong dialysis session — kahit pagod o may pupuntahan — at sundin ang nutrisyon na may sapat na protina.
4. Magtanong bago magsimula ng anumang bagong supplement, herbal product, o "energy" drink — marami sa mga ito ang tahimik na humahadlang sa iron, EPO, o sa iyong bato.
5. Dalhin ang gabay na ito at ang iyong mga tanong sa susunod na bisita. Ang aming layunin ay matatag at ligtas na hemoglobin — hindi "perpektong" numero sa lab. Ang pakiramdam at kaligtasan ay mas mahalaga kaysa sa numero lamang.1. Inuma ang iron ug uban pang supplements sumala sa reseta, ug ayaw laktawi ang mga lab appointments — gisubay ang imong iron ug pamamaga pinaagi sa blood tests.
2. Isulti kanamo ang bisan unsang timailhan sa impeksyon (hilanat, pagpula o nana sa access site, sakit sa ngipon, samad sa tiil), pagdugo (itom o pulang lubay, kusog nga regla, pagdugo sa ilong), o bag-ong kapoy.
3. Humanon ang tibuok dialysis session — bisan kapoy ka o adunay laing buhaton — ug sundon ang nutrisyon nga adunay sapat nga protina.
4. Pangutana sa wala pa magsugod og bisan unsang bag-ong supplement, herbal product, o "energy" drink — daghan niini ang hilom nga nagpugong sa iron, EPO, o sa imong kidney.
5. Dad-a kining giya ug ang imong mga pangutana sa sunod nga bisita. Ang among tumong mao ang malig-on ug luwas nga hemoglobin — dili "perpektong" numero sa lab. Ang pamati ug kaluwasan mas importante kaysa sa numero lamang.1. Inumin ing iron at aliwa pang supplements ayon king reseta, at e laktawan ing deng lab appointments — sinusubaybayan ing kekang iron at pamamaga king pamamagitan ning blood tests.
2. Sabihin kekami ing anumang tanda ning impeksyon (lagnat, pamumula o nana king access site, sakit ning ngipin, sugat king bitis), pagdurugo (itim o pulang dumi, makalat a regla, balinguyngoy), o bagong pagod.
3. Tapusin ing buong dialysis session — kahit pagod o atin pupuntahan — at sundin ing nutrisyon a atin sapat a protina.
4. Magtanong bayu magsimula ning anumang bagong supplement, herbal product, o "energy" drink — dacal king deng ini ya tahimik a humahadlang king iron, EPO, o king kekang batu.
5. Dalhin ing gabay a ini at ing kekang deng tanong king susunod a bisita. Ing kekami layunin ya matatag at ligtas a hemoglobin — ali "perpektong" numero king lab. Ing pakiramdam at kaligtasan ya mas mahalaga kesa king numero lamang.

05 · When to call05 · Kailan tatawag05 · Kanus-a motawag05 · Kailan tatawag

Warning signs — when to call your kidney teamMga babala — kailan tatawag sa kidney teamMga pasidaan — kanus-a motawag sa kidney teamDeng babala — kailan tatawag king kidney team

Square patient safety card listing six red flags during EPO-resistant anemia treatment — sudden energy drop or paleness, black/tarry/bloody stools, very heavy menstrual bleeding, fever or pus at the dialysis access, severe dental pain or foot wound, chest pain or stroke signs — with a red 'Call your unit or go to the ER — don't wait' footer.

A fridge-friendly safety card listing the six warning signs to call about right away — sudden energy drop or paleness, bleeding from the stomach or bowel, very heavy menstrual bleeding, fever or pus at the dialysis access, severe dental pain or a foot wound, and chest pain or stroke signs. Call your dialysis unit or go to the ER — don't wait for your next clinic visit.

⚠️

Call promptly if any of these appearTumawag agad kung lumitaw ang alinman sa mga itoTawag dayon kung mogawas ang bisan unsa niiniTumawag agad nung lumitaw ing alinman king deng ini

A sudden, severe drop in energy or paleness after weeks of stable injections; black, tarry, or bloody stools, vomiting blood, or sudden very heavy menstrual bleeding; fever, chills, redness, or pus at a dialysis catheter or fistula; severe dental pain, foot wound, or new abscess; chest pain, sudden one-sided weakness, slurred speech, or vision loss (possible stroke). With any of these, contact your dialysis unit or go to the emergency room — do not wait for your next clinic visit.Biglaang at malubhang pagbaba ng lakas o pamumutla pagkatapos ng linggo ng matatag na iniksyon; itim, parang tar, o madugong dumi, pagsusuka ng dugo, o biglaang napakalakas na regla; lagnat, panginginig, pamumula, o nana sa dialysis catheter o fistula; matinding sakit ng ngipin, sugat sa paa, o bagong abscess; sakit ng dibdib, biglaang panghihina sa isang gilid, hindi malinaw na pagsasalita, o pagkawala ng paningin (posibleng stroke). Sa alinman sa mga ito, tumawag sa dialysis unit o pumunta sa emergency room — huwag maghintay sa susunod na bisita.Kalit ug grabe nga paghulog sa kusog o pagpula human sa mga semana sa malig-on nga iniksyon; itom, parang tar, o dugoon nga lubay, pagsuka og dugo, o kalit kaayong kusog nga regla; hilanat, kurog, pagpula, o nana sa dialysis catheter o fistula; grabe nga sakit sa ngipon, samad sa tiil, o bag-ong abscess; sakit sa dughan, kalit nga kahuyang sa usa ka kilid, dili klaro nga pagsulti, o pagkawala sa panan-aw (posible nga stroke). Sa bisan unsa niini, tawag sa dialysis unit o adto sa emergency room — ayaw paghulat sa sunod nga bisita.Biglaang at malubhang pagbaba ning lakas o pamumutla kaybat ning linggo ning matatag a iniksyon; itim, parang tar, o madugong dumi, pagsusuka ning daya, o biglaang napakalakas a regla; lagnat, panginginig, pamumula, o nana king dialysis catheter o fistula; matinding sakit ning ngipin, sugat king bitis, o bagong abscess; sakit ning dibdib, biglaang panghihina king metung a gilid, ali malinaw a pagsasalita, o pagkawala ning paningin (posibleng stroke). King alinman king deng ini, tumawag king dialysis unit o pumunta king emergency room — e maghintay king susunod a bisita.

This guide is general patient education and is not a substitute for personal medical advice. Your treatment plan is tailored to you — please ask Dr. Rivero about your specific situation.Ang gabay na ito ay pangkalahatang edukasyon at hindi kapalit ng personal na payo sa medikal. Ang iyong plano ng paggamot ay nakatutok sa iyo — itanong kay Dr. Rivero ang iyong partikular na sitwasyon.Kining giya kay kinatibuk-ang edukasyon ug dili kapuli sa personal nga tambag sa medisina. Ang imong plano sa pagtambal naka-angkla kanimo — pangutana kang Dr. Rivero bahin sa imong partikular nga sitwasyon.Ing gabay a ini ya pangkalahatang edukasyon at ali kapalit ning personal a payu king medikal. Ing kekang plano ning paggamut ya nakatutok keka — itanong kang Dr. Rivero ing kekang partikular a sitwasyon.

Section 1 · Definitions & Thresholds

What "ESA hyporesponsiveness" actually means

There is no single accepted definition of ESA hyporesponsiveness — and the incidence reported varies several-fold by the definition applied. In a single real-world cohort of 85,259 dialysis patients, the same population yielded incidence figures of 5.2% (NICE), 15.4% (KDIGO), 40.7% (ERI), and 47.9% by a clinical-practicality algorithm. Tellingly, hyporesponsive patients received higher ESA doses yet reached similar hemoglobin — the signature of dose escalation without substrate correction (Atzinger 2024, PMID 39581908).

KDIGO operational definition

The Erythropoietin Resistance Index (ERI)

ERI is the most widely used quantitative metric:

ERI = weekly ESA dose (U) ÷ body weight (kg) ÷ Hb (g/dL)

Higher ERI = more drug per kilogram of patient buying less hemoglobin. Reported thresholds are heterogeneous, and the cutoff chosen materially changes who is labeled "resistant":

Metric / thresholdDefinition usedSource
ERI ≥ 2.0 U/kg/wk per g/LHyporesponse (USRDS Medicare cohort)Cizman 2020, PMID 33089137
ERI ≥ 1.5–2.0 U/kg/wk per g/LPrespecified HypoR1–3 definitionsMcCausland 2025, PMID 40333020
ESA dose > 300 IU/kg/wkFrank ESA resistanceSaudan 2006, PMID 16523432
EPO > 150 U/kg/wk (PD)EPO hyporesponse in peritoneal dialysisMakruasi 2016, PMID 29901907
Compute it
∑
ESA Resistance Index (ERI) calculator
Enter weekly ESA dose, weight, and Hb — get ERI in U/kg/wk per g/dL with KDIGO-aligned interpretation. Trend it visit-to-visit instead of chasing an absolute cutoff.
Open →
📈

Practical reading

Use ERI longitudinally on the same patient rather than chasing an absolute cutoff. A rising ERI at stable Hb is an early warning to launch the workup below — before the dose climbs into the harm zone.

Section 2 · Epidemiology & Prognosis

Hyporesponsiveness is not a benign laboratory curiosity

It is a potent, independent marker of adverse outcomes — and the high ESA doses used to chase it are themselves a hazard.

Section 3 · Pathophysiology

A mechanism-first map: substrate & milieu, not the signal

Anemia of CKD has two engines — relative EPO deficiency (the failing kidney under-produces erythropoietin) and iron-restricted erythropoiesis under hepcidin control. Resistance to exogenous ESA is overwhelmingly a problem of the second engine plus a suppressive milieu, not of EPO signaling per se (Babitt & Lin 2012, PMID 22935483; Weir 2021, PMID 34280923).

The hepcidin–ferroportin axis — the central lesion

Review-article biomedical mechanism figure: organ-level panel (kidney + liver + bone marrow + circulating macrophage and enterocyte) with IL-6 driving hepatic HAMP transcription; magnified macrophage inset showing hepcidin docking onto ferroportin, ferroportin endocytosis and degradation, and iron sequestration; bottom injury → intervention → benefit summary flow.

The IL-6 → hepcidin → ferroportin axis is the central lesion of ESA hyporesponsiveness. Inflammation drives hepatic hepcidin; hepcidin internalizes ferroportin on macrophages and enterocytes; iron is trapped intracellularly; the marrow is iron-starved despite normal-to-high ferritin. Intervention targets inflammation, proactive IV iron, HIF-PHIs (lower hepcidin, raise transferrin/TIBC), and emerging anti-IL-6 (ziltivekimab).

FPN
ferroportin
HAMP
hepcidin antimicrobial peptide gene
HIF-PHI
hypoxia-inducible factor prolyl hydroxylase inhibitor
TIBC
total iron-binding capacity

Pro-inflammatory cytokines — IL-6 chief among them — drive hepatic hepcidin synthesis. Hepcidin binds and degrades ferroportin, the sole cellular iron-export channel, trapping iron inside enterocytes and macrophages. The result is functional (iron-restricted) erythropoiesis: ferritin is normal or high, yet iron cannot reach the marrow. Inflammation simultaneously suppresses erythroid progenitor proliferation and blunts the hypoxia response — a triple hit on the erythron (Weir 2021; Icardi 2013).

Drivers, mechanisms, and the evidence behind each

DriverMechanismKey evidence
Iron deficiency
(absolute & functional)		Most common cause. Absolute depletion of stores or hepcidin-mediated sequestration despite adequate stores — limits substrate for hemoglobinization.Tanaka 2015, PMID 26381391
Inflammation
(IL-6, CRP)		Drives hepcidin; suppresses progenitors; impairs hypoxia sensing. The dominant driver of true resistance.Weir 2021; Babitt 2012
CKD-MBD / secondary hyperparathyroidismPTH as uremic toxin; marrow fibrosis (osteitis fibrosa); FGF23 implicated. PTH >800 pg/mL over-represented in hyporesponders.Tanaka 2018, PMID 29767854; Cizman 2020
Uremic toxins
(indoxyl sulfate)		Suppresses EPO transcription via the HIF pathway, disrupts iron metabolism, shortens RBC survival, amplifies oxidative stress — a self-reinforcing cycle.Rattanasompattikul 2025, PMID 41355384
Malnutrition / PEWProtein-energy wasting independently predicts poor EPO response; only non-PEW patients achieved Hb gains. Low albumin tracks the highest ERI tertile.González-Ortiz 2019, PMID 31412807
Vitamin deficiency
(D, B12, folate, C)		Vitamin D deficiency promotes ESA resistance via inflammation; repletion lowered ERI, CRP, ferritin, iPTH. B12/folate needed for erythropoiesis; vitamin C aids iron mobilization.Icardi 2013; Nand 2017, PMID 28457030
Blood loss / shortened RBC survivalDialysis-circuit and GI losses, platelet dysfunction, RBC fragmentation, uremic hemolysis — ongoing iron drain and lower Hb yield.Gembillo 2025, PMID 41024950
Anti-EPO antibody PRCARare but serious — neutralizing antibodies cause pure red cell aplasia. Sudden Hb fall with reticulocytopenia on ESA. Stop ESA immediately.Hashimoto 2016, PMID 27338269; Wu 2020, PMID 32856389
Carnitine deficiencyDialysis-related depletion; L-carnitine reduced ERI (MD −2.72) in meta-analysis and cut ERI 25% vs 3% (placebo) in a dedicated RCT of ESA-hyporesponsive HD patients.Zhu 2021, PMID 33713287; Reuter 2026, J Ren Nutr
OtherMalignancy, occult infection, hemoglobinopathy/hemolysis, recent COVID-19 (months-long hepcidin-driven resistance), androgen deficiency.Gembillo 2025; Dasgupta 2025, PMID 41136869
🔬

On ACE inhibitors / ARBs

Frequently cited as a cause, but the largest cross-sectional study (515 HD patients) found no association between ACEi or ARB use and ESA resistance. Do not reflexively stop renin-angiotensin blockade — the cardiorenal benefit almost always outweighs a theoretical erythropoietic cost (Saudan 2006, PMID 16523432).

Five-organ monoline crosstalk sigil — kidney, liver, bone marrow, gut, and parathyroid arranged in a pentagon around a central 'Inflamed iron-restricted erythron · ESA hyporesponse' hub, connected by labeled dotted arrows (EPO ↓, hepcidin ↑, indoxyl sulfate, IL-6, iron, PTH ↑).

A simple five-organ sigil summarizes the multi-organ inflammatory iron-restricted phenotype that drives ESA hyporesponse — not a single-axis EPO failure. Kidney supplies less EPO and more indoxyl sulfate; liver drives hepcidin under IL-6; gut absorption and macrophage iron egress collapse; the marrow erythron is iron-starved and progenitor-suppressed; parathyroid contributes marrow fibrosis. Therapy must address the milieu, not just the signal.

SHPT
secondary hyperparathyroidism
HIF
hypoxia-inducible factor
Section 4 · Diagnostic Workup

A cause-directed algorithm — find the lesion before climbing the dose

When ERI rises or Hb stalls despite adequate weight-based ESA, work the problem in this sequence. The goal is to find the correctable lesion before the dose is escalated.

Portrait AHA-style clinical algorithm: ten numbered nodes for the EPO-hyporesponse workup (confirm & quantify; iron status first; inflammation/infection; nutrition; CKD-MBD; dialysis adequacy; vitamins/cofactors; blood loss/hemolysis; PRCA red-flag branch; medication & comorbidity review) with a final dose-ceiling escalation node.

Cause-directed workup before ESA escalation. The PRCA branch breaks off to the right (sudden Hb fall + reticulocytopenia on ESA → stop ESA → anti-EPO antibody assay). The bottom escalation node summarizes the safer endpoint when workup is unrevealing — cap ESA at ~2× weight-based, consider HIF-PHI, tolerate Hb 10–11.5 g/dL.

ERI
erythropoietin resistance index
SHPT
secondary hyperparathyroidism
PRCA
pure red cell aplasia
EPO-Hyporesponse Workup — 10 Steps
1
Confirm & quantify

Apply a definition (KDIGO dose-escalation criteria and/or ERI). Verify adherence, ESA storage, and administration technique.

2
Iron status first

Ferritin and TSAT. KDIGO thresholds: a trial of iron is reasonable when TSAT ≤ 30% and ferritin ≤ 500 ng/mL. Distinguish absolute from functional deficiency (Tanaka 2015).

3
Inflammation / infection

CRP/hsCRP (± IL-6). Hunt occult infection — vascular access, retained catheters, failed grafts, dental and foot sources (Icardi 2013).

4
Nutrition

Albumin, Malnutrition-Inflammation Score; address protein-energy wasting (González-Ortiz 2019).

5
CKD-MBD

Intact PTH — look for severe secondary hyperparathyroidism (especially >800 pg/mL) and treat (Tanaka 2018).

6
Dialysis adequacy

Kt/V; inadequate clearance raises indoxyl sulfate and suppresses erythropoiesis (Rattanasompattikul 2025).

7
Vitamins / cofactors

B12, folate, 25-OH vitamin D; consider vitamin C and L-carnitine in selected patients.

8
Blood loss / hemolysis

Reticulocyte count, LDH, haptoglobin, peripheral smear; evaluate GI and circuit losses.

9
Red flag — suspect PRCA

Sudden severe Hb fall with reticulocytopenia on ESA → stop ESA, check anti-EPO antibodies and marrow; treat with immunosuppression ± HIF-PHI (Hashimoto 2016).

10
Medication & comorbidity review

Malignancy, hemoglobinopathy, recent COVID-19; reassess but do not reflexively stop RAS blockade.

Workup calculators
∑
ESA Resistance Index (ERI)
Quantify hyporesponse and trend it longitudinally before escalating ESA.
Open →
⚖️
Iron status — TSAT & ferritin
Classify absolute vs functional iron deficiency against KDIGO thresholds.
Open →
∑
Ganzoni iron deficit
Total iron deficit for IV repletion when initiating proactive iron.
Open →
💉
IV iron dose
Per-product dosing for FCM, iron sucrose, and ferric derisomaltose.
Open →
📐
ESA dose adjustment
Apply the dose-ceiling principle when Hb stalls or overshoots.
Open →
🦴
CKD-MBD
PTH, calcium, phosphate workflow for the hyporesponsive patient with high PTH.
Open →
🍽️
Nutrition / MIS screening
Flag protein-energy wasting as a driver of poor EPO response.
Open →
Section 5 · Targets & Landmark Trials

Why we do not chase normal hemoglobin

The single most important lesson of two decades of trials: fully correcting hemoglobin with ESAs causes harm without symptomatic benefit. The dose ceiling in hyporesponsiveness is a safety principle, not an admission of defeat.

Two-column clinician reference poster — left: five-row landmark trials strip (Normal Hematocrit, CHOIR, CREATE, TREAT, PIVOTAL) with population, key result, and lesson; right: five KDIGO 2026 tiles (Hb initiation thresholds, Hb ceiling, iron trial thresholds, HIF-PHI positioning, KDIGO 2026 nomenclature); bottom take-home strip 'The dose ceiling in hyporesponse is a safety principle — not an admission of defeat.'

A single-page evidence reference: five landmark trials on the left explain why pushing Hb to normal harms — including the TREAT stroke signal (HR 1.92) — and KDIGO 2026 targets on the right summarize initiation thresholds, the Hb ceiling (do not maintain > 11.5; do not intentionally exceed 13), iron-trial thresholds (TSAT ≤ 30%, ferritin ≤ 500), HIF-PHI positioning (offer to patients who cannot tolerate or do not respond to ESA), and the renamed nomenclature.

NDD
non-dialysis-dependent CKD
HR
hazard ratio
RR
relative risk

KDIGO targets — 2012 → 2026

ParameterKDIGO 2012KDIGO 2026 update
ESA initiation (non-dialysis)Consider when Hb < 10 g/dL; individualizeMost can initiate at Hb threshold 8.5–10.0 g/dL
ESA initiation (dialysis)Avoid Hb falling < 9; start 9–10 g/dLInitiate when Hb 9.0–10.0 g/dL
Hb ceilingDo not maintain > 11.5; do not intentionally exceed 13 g/dLConservative ceiling retained; individualized
First-line agentESAESA preferred over HIF-PHI
HIF-PHI role— (not yet available)Offer to patients who cannot tolerate or do not respond to ESAs
Iron — trial of IV ironTSAT ≤ 30% and ferritin ≤ 500 ng/mLMore proactive thresholds, especially in hemodialysis

Source: Drüeke & Parfrey 2012 (PMID 22854645); KDIGO 2026 Executive Summary, Babitt/Tonelli, Kidney Int 2026 (PMID 41485807); KDOQI US commentary, Jalal 2026 (PMID 42095795); ERBP commentary, Del Vecchio 2026 (PMID 41604211).

⚠️

Nomenclature note (KDIGO 2026)

"Absolute iron deficiency" is renamed systemic iron deficiency; "functional iron deficiency" is renamed iron-restricted erythropoiesis. Anemia is defined as Hb < 12 g/dL (women) and < 13 g/dL (men).

Landmark trials behind the ceiling

TrialPopulation / targetKey resultLesson
Normal Hematocrit
Besarab 1998		1,233 HD with cardiac disease; Hct 42% vs 30%Death/MI RR 1.3 (0.9–1.9); stopped early; more access thrombosisNormalizing Hct harms
CHOIR
Singh 2006		1,432 NDD; Hb 13.5 vs 11.3 g/dLComposite HR 1.34 (1.03–1.74); no QoL benefitHigher target = harm
CREATE
Drüeke 2006		603 stage 3–4; Hb 13–15 vs 10.5–11.5CV HR 0.78 (0.53–1.14), NS; more dialysis in high armNo CV benefit
TREAT
Pfeffer 2009		4,038 T2DM NDD; darbepoetin to ~13 vs placeboStroke HR 1.92 (1.38–2.68); no CV/renal benefitThe stroke signal
Section 6 · Therapeutic Strategy

Sequencing therapy in the resistant patient

The order matters: (1) correct the cause from the workup; (2) optimize iron; (3) hold ESA at a rational ceiling; (4) for true ESA intolerance or non-response, consider a HIF-PHI; (5) treat the inflammatory and metabolic milieu. Escalating ESA into the harm zone is the option of last resort, not first.

6.1 Iron optimization — the highest-yield lever

🧪

Ferric carboxymaltose & hypophosphatemia — a nutrition-aware caution

FCM uniquely causes FGF23-mediated hypophosphatemia (vs ferric derisomaltose, OR 38.4; severe <1.0 mg/dL in 11.3%), with rises in iFGF23, PTH, and ALP and falls in 1,25(OH)₂D — a mechanistic route to osteomalacia and fractures with repeated dosing. Check phosphate in patients receiving recurrent FCM (Schaefer/Wolf 2022, PMID 34850000; Zoller 2023, PMID 36343979).

6.2 ESA management — hold the line

6.3 HIF-prolyl hydroxylase inhibitors (HIF-PHIs)

Mechanistic appeal in the inflamed patient. Oral HIF-PHIs stabilize HIF-α, restoring near-physiologic endogenous EPO while lowering hepcidin and raising transferrin/TIBC — acting around the inflammatory iron block rather than overpowering it with supraphysiologic EPO (Singh 2021, PMID 34739196).

The key hyporesponsiveness data. In the OLYMPUS inflamed subgroup (411 patients with elevated hs-CRP), roxadustat raised Hb by +1.75 g/dL vs +0.62 with placebo — the full erythropoietic effect was preserved despite inflammation (Fishbane 2021, PMID 33842503). A 20-RCT meta-analysis found roxadustat maintenance dose was independent of baseline CRP/hsCRP, positioning HIF-PHIs precisely where ESA is hyporesponsive due to iron deficiency and inflammation (Zheng 2023).

AgentPivotal CV / efficacy dataMACE vs comparatorRegulatory status
Daprodustat
(Jesduvroq)		ASCEND-D & ASCEND-ND (Singh NEJM 2021); Hb non-inferior to ESADD HR 0.93 (0.81–1.07); NDD HR 1.03 (0.89–1.19) — both met NIFDA-approved dialysis-only (Feb 2023); boxed thrombosis warning
Vadadustat
(Vafseo)		INNO2VATE / PRO2TECT (Eckardt / Chertow NEJM 2021)DD HR 0.96 (0.83–1.11) met NI; NDD HR 1.17 (1.01–1.36) failed NIFDA dialysis-only (Mar 2024)
Roxadustat
(Evrenzo)		OLYMPUS / ROCKIES / ALPS / HIMALAYAS; strong in inflamed subgroup; lowers LDLNDD pooled MACE HR 1.10 (0.96–1.27)NOT FDA-approved (CRL 2021); approved EU, China, Japan
Desidustat / Molidustat / EnarodustatNon-inferior to ESA in regional phase 3; desidustat lowers hepcidinNo CV separation in available dataRegional (India, Japan)
📌

Positioning HIF-PHIs (KDIGO 2026)

ESAs remain first-line. HIF-PHIs are offered to patients who cannot tolerate or do not respond to ESAs — exactly the hyporesponsive phenotype — with oral dosing advantageous in non-dialysis, PD, and home-HD. Avoid in active malignancy, recent thrombosis, children, and transplant recipients. A retracted roxadustat pooled CV-benefit paper (Kidney Int Rep 2020) should not be cited.

6.4 Adjuncts & the integrative milieu

Section 7 · Clinical Decision Points

At a glance — pattern recognition for the resistant patient

If you see…Do this
Rising ERI at stable HbLaunch the workup before escalating ESA
TSAT ≤ 30% and ferritin ≤ 500Trial of iron — IV in HD (proactive, PIVOTAL); weigh IV vs oral in NDD (REVOKE caution)
High ferritin + high CRPFunctional iron block from inflammation — hunt occult infection; HIF-PHI candidate if ESA-hyporesponsive
PTH > 800 pg/mLTreat secondary hyperparathyroidism; reassess erythropoietic response
Dose at ~2–4× weight-based with stalled HbStop climbing; reassess cause; consider HIF-PHI; tolerate Hb 10–11.5
Sudden Hb fall + reticulocytopenia on ESAStop ESA; check anti-EPO antibodies; suspect PRCA
Recurrent ferric carboxymaltoseMonitor serum phosphate (FGF23-mediated hypophosphatemia)
When is escalating ESA still acceptable?
When the workup is unrevealing, iron and PTH are optimized, inflammation is being managed, and the patient remains symptomatic at the floor of the target range. Even then, cap at roughly 2× the initial weight-based dose and revisit the workup at every escalation. A "negative" workup at one time point is not a license to climb indefinitely.
Should HIF-PHIs replace ESAs in hyporesponders?
No — they are positioned where ESA fails or is intolerated. The strongest signal favoring HIF-PHIs in this niche is the OLYMPUS inflamed subgroup; the CV-safety picture differs by agent and population, and a careful read of ASCEND, INNO2VATE / PRO2TECT, and the regulatory record is non-negotiable before switching.
Is L-carnitine a "fad supplement"?
In ESA-hyporesponsive HD patients, no — a randomized double-blind placebo-controlled trial showed a 25% reduction in ERI vs 3% with placebo, supported by an 18-RCT meta-analysis (MD −2.72). The mechanism (membrane stabilization, extended RBC lifespan) is biologically coherent. Reserve it for genuine hyporesponders rather than as a routine ESA companion.
ReferencesMga SanggunianMga TinubdanReng Reperensya 39 sources
  1. Babitt, J. L., Berns, J. S., Bozkurt, B., Cheung Khedairy, R. S., Cuevas, Y., Effa, E. E., Eisenga, M. F., Fishbane, S., Ginzburg, Y. Z., Haase, V. H., Hedayati, S. S., Kim, S., Moura-Neto, J. A., Nagler, E. V., Rossignol, P., Sahay, M., Tanaka, T., Yee-Moon Wang, A., Wheeler, D. C., ... Tonelli, M. (2026). Executive summary of the KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD). Kidney International, 109(1), 44–56. https://doi.org/10.1016/j.kint.2025.06.005
  2. Jalal, D. I., Bansal, N., Cho, M. E., Fishbane, S., Gutierrez, O. M., Kovesdy, C. P., Kshirsagar, A., Spinowitz, B., & Wish, J. (2026). KDOQI US commentary on the KDIGO 2026 clinical practice guideline for the management of anemia in CKD. American Journal of Kidney Diseases, 88(1), 1–17. https://doi.org/10.1053/j.ajkd.2026.03.036
  3. Del Vecchio, L., Cases, A., Eisenga, M. F., Małyszko, J., Barratt, J., & Bolignano, D. (2026). KDIGO 2026 clinical practice guideline for anemia in chronic kidney disease (CKD): A commentary from the European renal best practice (ERBP). Nephrology, Dialysis, Transplantation. https://doi.org/10.1093/ndt/gfag014
  4. Drüeke, T. B., & Parfrey, P. S. (2012). Summary of the KDIGO guideline on anemia and comment: Reading between the (guide)line(s). Kidney International, 82(9), 952–960. https://doi.org/10.1038/ki.2012.270
  5. Atzinger, C., Arens, H. J., Neri, L., Arkossy, O., Garbelli, M., Jiletcovici, A., Snijder, R., Leyland, K., Khalife, N., Ali, M., & Feuersenger, A. (2024). Hyporesponsiveness to erythropoiesis-stimulating agents in dialysis-dependent patients with anaemia of chronic kidney disease: A retrospective observational study. Advances in Therapy, 42(1), 471–489. https://doi.org/10.1007/s12325-024-03015-4
  6. McCausland, F. R., Waikar, S. S., Claggett, B., McMahon, G. M., Neto, O. M. V., Rastogi, A., Praditpornsilpa, K., Correa-Rotter, R., Kher, V., Del Vecchio, L., Solomon, S. D., & Singh, A. K. (2025). Association of different definitions of erythropoiesis-stimulating agent hyporesponsiveness with major adverse cardiovascular events: Insights from ASCEND-D. Kidney360, 6(9), 1541–1548. https://doi.org/10.34067/KID.0000000808
  7. Cizman, B., Smith, H. T., Camejo, R. R., Casillas, L., Dhillon, H., Mu, F., Wu, E., Xie, J., Zuckerman, P., & Coyne, D. (2020). Clinical and economic outcomes of erythropoiesis-stimulating agent hyporesponsiveness in the post-bundling era. Kidney Medicine, 2(5), 589–599.e1. https://doi.org/10.1016/j.xkme.2020.06.008
  8. Hayashi, T., Joki, N., Tanaka, Y., Iwasaki, M., Kubo, S., Matsukane, A., Takahashi, Y., Imamura, Y., Hirahata, K., & Hase, H. (2019). Resistance to erythropoiesis-stimulating agents in pre-dialysis and post-dialysis mortality in Japanese incident hemodialysis patients. Blood Purification, 47 Suppl 2(Suppl 1), 31–37. https://doi.org/10.1159/000496634
  9. Weir, M. R. (2021). Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents. American Journal of Nephrology, 52(6), 450–466. https://doi.org/10.1159/000516901
  10. Babitt, J. L., & Lin, H. Y. (2012). Mechanisms of anemia in CKD. Journal of the American Society of Nephrology, 23(10), 1631–1634. https://doi.org/10.1681/ASN.2011111078
  11. Tanaka, S., & Tanaka, T. (2015). How to supplement iron in patients with renal anemia. Nephron, 131(2), 138–144. https://doi.org/10.1159/000440773
  12. Portoles, J., Serrano Salazar, M. L., González Peña, O., Gallego Domínguez, S., Vera Rivera, M., Caro Espada, J., Herreros García, A., Munar Vila, M. A., José Espigares Huete, M., Sosa Barrios, H., Paraíso, V., Mariscal de Gante, L., Bajo, M. A., Mijaylova, A. G., Pascual Pajares, E., Areste Fosalba, N., Espinel, L., Tornero Molina, F., Pizarro Sánchez, S., ... Quiroga, B. (2023). Opportunities to improve the management of anemia in peritoneal dialysis patients: Lessons from a national study in routine clinical practice. Clinical Kidney Journal, 16(12), 2493–2502. https://doi.org/10.1093/ckj/sfad152
  13. Tanaka, M., Komaba, H., & Fukagawa, M. (2018). Emerging association between parathyroid hormone and anemia in hemodialysis patients. Therapeutic Apheresis and Dialysis, 22(3), 242–245. https://doi.org/10.1111/1744-9987.12685
  14. Rattanasompattikul, M., Srithongkul, T., Tantisattamo, E., Kalantar-Zadeh, K., & Noppakun, K. (2025). Indoxyl sulfate: Clinical implications for anemia management in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 35(3), 387–393. https://doi.org/10.1097/MNH.0000000000001145
  15. González-Ortiz, A., Correa-Rotter, R., Vázquez-Rangel, A., Vega-Vega, O., & Espinosa-Cuevas, Á. (2019). Relationship between protein-energy wasting in adults with chronic hemodialysis and the response to treatment with erythropoietin. BMC Nephrology, 20(1), 316. https://doi.org/10.1186/s12882-019-1457-0
  16. Icardi, A., Paoletti, E., De Nicola, L., Mazzaferro, S., Russo, R., & Cozzolino, M. (2013). Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: The potential role of inflammation. Nephrology, Dialysis, Transplantation, 28(7), 1672–1679. https://doi.org/10.1093/ndt/gft021
  17. Nand, N., & Mittal, R. (2017). Evaluation of effect of vitamin D deficiency on anemia and erythropoietin hyporesponsiveness in patients of chronic kidney disease. The Journal of the Association of Physicians of India, 65(2), 38–42. https://pubmed.ncbi.nlm.nih.gov/28457030/
  18. Gembillo, G., Peritore, L., Spadaro, G., Cuzzola, F., Calderone, M., Messina, R., Di Piazza, S., Sudano, F., Gambuzza, M. E., Princiotto, M., Soraci, L., & Santoro, D. (2025). Kidney involvement and anemia in COVID-19 infection. World Journal of Nephrology, 14(3), 107582. https://doi.org/10.5527/wjn.v14.i3.107582
  19. Hashimoto, K., Harada, M., & Kamijo, Y. (2016). Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus. International Journal of Hematology, 104(4), 502–505. https://doi.org/10.1007/s12185-016-2047-6
  20. Wu, Y., Cai, X., Ni, J., & Lin, X. (2020). Resolution of epoetin-induced pure red cell aplasia, successful re-challenge with roxadustat. International Journal of Laboratory Hematology, 42(6), e291–e293. https://doi.org/10.1111/ijlh.13325
  21. Zhu, Y., Xue, C., Ou, J., Xie, Z., & Deng, J. (2021). Effect of L-carnitine supplementation on renal anemia in patients on hemodialysis: A meta-analysis. International Urology and Nephrology, 53(10), 2149–2158. https://doi.org/10.1007/s11255-021-02835-5
  22. Reuter, S. E., Steiber, A. L., Faull, R. J., & Evans, A. M. (2026). Effectiveness of L-carnitine for the treatment of erythropoietin-resistant renal anemia: A randomized, double-blind, placebo-controlled pilot trial. Journal of Renal Nutrition, 36(3), 491–501. https://doi.org/10.1053/j.jrn.2026.01.008
  23. Saudan, P., Halabi, G., Perneger, T., Wasserfallen, J. B., Wauters, J. P., & Martin, P. Y. (2006). ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. Journal of Nephrology, 19(1), 91–96. https://pubmed.ncbi.nlm.nih.gov/16523432/
  24. Dasgupta, I., Minutolo, R., Bell, S., Eken, V., Heirman, N., Peatman, J., Perry, R., Sánchez-Álvarez, J. E., Shah, S., Stone, M., Ureña Torres, P. A., Val-Marañes, L., & Krüger, T. (2025). A European delphi study on the management of anaemia of CKD: Unmet needs in personalized treatment. Journal of Nephrology, 38(9), 2851–2860. https://doi.org/10.1007/s40620-025-02422-2
  25. Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998). The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. The New England Journal of Medicine, 339(9), 584–590. https://doi.org/10.1056/NEJM199808273390903
  26. Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006). Correction of anemia with epoetin alfa in chronic kidney disease. The New England Journal of Medicine, 355(20), 2085–2098. https://doi.org/10.1056/NEJMoa065485
  27. Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K. U., Macdougall, I. C., Tsakiris, D., Burger, H. U., & Scherhag, A. (2006). Normalization of hemoglobin level in patients with chronic kidney disease and anemia. The New England Journal of Medicine, 355(20), 2071–2084. https://doi.org/10.1056/NEJMoa062276
  28. Pfeffer, M. A., Burdmann, E. A., Chen, C. Y., Cooper, M. E., de Zeeuw, D., Eckardt, K. U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J. B., McMurray, J. J., Parfrey, P., Parving, H. H., Remuzzi, G., Singh, A. K., Solomon, S. D., & Toto, R. (2009). A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. The New England Journal of Medicine, 361(21), 2019–2032. https://doi.org/10.1056/NEJMoa0907845
  29. Macdougall, I. C., White, C., Anker, S. D., Bhandari, S., Farrington, K., Kalra, P. A., McMurray, J. J. V., Murray, H., Tomson, C. R. V., Wheeler, D. C., Winearls, C. G., & Ford, I. (2018). Intravenous iron in patients undergoing maintenance hemodialysis. The New England Journal of Medicine, 380(5), 447–458. https://doi.org/10.1056/NEJMoa1810742
  30. Macdougall, I. C., Bock, A. H., Carrera, F., Eckardt, K. U., Gaillard, C., Van Wyck, D., Roubert, B., Nolen, J. G., & Roger, S. D. (2014). FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology, Dialysis, Transplantation, 29(11), 2075–2084. https://doi.org/10.1093/ndt/gfu201
  31. Agarwal, R., Kusek, J. W., & Pappas, M. K. (2015). A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International, 88(4), 905–914. https://doi.org/10.1038/ki.2015.163
  32. Schaefer, B., Zoller, H., & Wolf, M. (2022). Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose. The Journal of Clinical Endocrinology & Metabolism, 107(4), 1009–1019. https://doi.org/10.1210/clinem/dgab852
  33. Zoller, H., Wolf, M., Blumenstein, I., Primas, C., Lindgren, S., Thomsen, L. L., Reinisch, W., & Iqbal, T. (2022). Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): A randomised clinical trial. Gut, 72(4), 644–653. https://doi.org/10.1136/gutjnl-2022-327897
  34. Singh, A. K., Carroll, K., McMurray, J. J. V., Solomon, S., Jha, V., Johansen, K. L., Lopes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., Wanner, C., Wheeler, D. C., Więcek, A., Blackorby, A., Cizman, B., Cobitz, A. R., Davies, R., DiMino, T. L., Kler, L., ... Perkovic, V. (2021). Daprodustat for the treatment of anemia in patients not undergoing dialysis. The New England Journal of Medicine, 385(25), 2313–2324. https://doi.org/10.1056/NEJMoa2113380
  35. Singh, A. K., Carroll, K., Perkovic, V., Solomon, S., Jha, V., Johansen, K. L., Lopes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., Wanner, C., Wheeler, D. C., Więcek, A., Blackorby, A., Cizman, B., Cobitz, A. R., Davies, R., Dole, J., Kler, L., ... McMurray, J. J. V. (2021). Daprodustat for the treatment of anemia in patients undergoing dialysis. The New England Journal of Medicine, 385(25), 2325–2335. https://doi.org/10.1056/NEJMoa2113379
  36. Fishbane, S., El-Shahawy, M. A., Pecoits-Filho, R., Van, B. P., Houser, M. T., Frison, L., Little, D. J., Guzman, N. J., & Pergola, P. E. (2021). Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized phase 3 study (OLYMPUS). Journal of the American Society of Nephrology, 32(3), 737–755. https://doi.org/10.1681/ASN.2020081150
  37. Eckardt, K. U., Agarwal, R., Aswad, A., Awad, A., Block, G. A., Bacci, M. R., Farag, Y. M. K., Fishbane, S., Hubert, H., Jardine, A., Khawaja, Z., Koury, M. J., Maroni, B. J., Matsushita, K., McCullough, P. A., Lewis, E. F., Luo, W., Parfrey, P. S., Pergola, P., ... Chertow, G. M. (2021). Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. The New England Journal of Medicine, 384(17), 1601–1612. https://doi.org/10.1056/NEJMoa2025956
  38. Chertow, G. M., Pergola, P. E., Farag, Y. M. K., Agarwal, R., Arnold, S., Bako, G., Block, G. A., Burke, S., Castillo, F. P., Jardine, A. G., Khawaja, Z., Koury, M. J., Lewis, E. F., Lin, T., Luo, W., Maroni, B. J., Matsushita, K., McCullough, P. A., Parfrey, P. S., ... Eckardt, K. U. (2021). Vadadustat in patients with anemia and non-dialysis-dependent CKD. The New England Journal of Medicine, 384(17), 1589–1600. https://doi.org/10.1056/NEJMoa2035938
  39. Kato, H., Nangaku, M., Hirakata, H., Wada, T., Hayashi, T., Sato, H., Yamazaki, Y., Masaki, T., Kagimura, T., Yamamoto, H., Hase, H., Kamouchi, M., Imai, E., Mizuno, K., Iwasaki, M., Akizawa, T., Tsubakihara, Y., Maruyama, S., & Narita, I. (2017). Rationale and design of observational clinical research in chronic kidney disease patients with renal anemia: Renal prognosis in patients with hyporesponsive anemia to erythropoiesis-stimulating agents, darbepoetin alfa (BRIGHTEN trial). Clinical and Experimental Nephrology, 22(1), 78–84. https://doi.org/10.1007/s10157-017-1427-4
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save

Related guides

Calculator
ESA Resistance Index (ERI) Calculator
Compute and trend ERI — the most widely used quantitative metric for ESA hyporesponsiveness.
Anemia
Anemia in Kidney Disease: Iron, EPO & Energy
The full anemia spine — iron-first principle, ESA targets, and dialysis-specific approach.
ESA Safety
More EPO Isn't Better: ESA Dose & Cancer Risk
Why pushing past the KDIGO Hb target — even on covered EPO — carries dose-related harm.
Iron
Understanding Iron in Kidney Disease
Absolute vs functional deficiency, IV iron products, hepcidin physiology.
CKD-MBD
CKD-Mineral & Bone Disorder
PTH, vitamin D, calcimimetics — and why severe SHPT blunts the EPO response.
Dialysis
Dialysis Adequacy
Kt/V and the uremic-toxin angle on poor EPO response.
Nutrition
Nutrition for Kidney Patients
Protein, energy, and the milieu that lets the marrow work.